Long-term Safety and Effectiveness of Natalizumab Treatment in Clinical Practice

J Neurol Neurosurg Psychiatry
Jul 08, 2020

Since the TOP 5-year interim analysis (December 2012), cohort size (6148 vs 4821), median exposure (3.3 vs 1.8 years) and median follow-up time (62 vs 26 months) have increased.

Read More

FDA Approves New HIV Treatment for Patients with Limited Treatment Options

FDA
Jul 07, 2020

FDA approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies

Read More

Rivaroxaban in Peripheral Artery Disease after Revascularization

NEJM
Jul 06, 2020

In patients with PAD who had undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, MI, ischemic stroke, or death from cardiovascular causes than aspirin alone.

Read More

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

NEJM
Jul 04, 2020

Multisystem inflammatory syndrome in children associated with SARS-CoV-2 led to serious and life-threatening illness in previously healthy children and adolescents.

Read More

CKD Increases Carbonylation of HDL and Is Associated with Impaired Antiaggregant Properties

JASN
Jul 03, 2020

HDL from CKD rabbits and patients on hemodialysis exhibited an impaired ability to inhibit platelet aggregation, suggesting that altered HDL properties may contribute to the increased cardiovascular risk in this population.

Read More

FDA Approves First-Line Immunotherapy

FDA
Jul 02, 2020

FDA approved Keytruda (pembrolizumab) for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Read More

Ten-Year Risks of Recurrent Stroke, Disability, Dementia and Cost in Relation to Site of Primary Intracerebral Haemorrhage

J Neurol Neurosurg Psychiatry
Jul 01, 2020

Compared with non-lobar ICH, the substantially higher 10-year risks of recurrent stroke, dementia and lower QALYs after lobar ICH highlight the need for more effective prevention for this patient group.

Read More

FDA Approves New Therapy for Dravet Syndrome

FDA
Jun 30, 2020

Fintepla (fenfluramine), a Schedule IV controlled substance approved by FDA for the treatment of seizures associated with Dravet syndrome in patients age 2 and older.

Read More

A Randomized, Placebo-Controlled Trial of Emricasan in Patients With NASH and F1-F3 Fibrosis

J Hepatology
Jun 29, 2020

Emricasan treatment did not improve liver histology in patients with NASH fibrosis despite target engagement and may have worsened fibrosis and ballooning.

Read More